Charting New Territories in the Management of Individuals with Immune-Mediated Inflammatory Disease and Obesity: Calming Concomitant Pathologies
Regulatory Update: Orforglipron – a daily, oral GLP-1 receptor agonist – received FDA approval on April 1, 2026, after the release of this educational activity.
PROGRAM CHAIR & FACULTY
Jerry Bagel, MD, MS
Director, Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
FEATURING
Robin Ciesielski
Burlington, New Jersey
PROGRAM OVERVIEW
This “Day in the Life” Docuseries program explores the shared immunologic mechanisms underlying obesity and immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease, psoriasis, and psoriatic arthritis. It highlights the key cytokines and signaling pathways that drive chronic inflammation and contribute to comorbid pathology. Attendees will review current obesity guidelines and supporting evidence to inform integrated care strategies for patients with IMIDs and excess body weight. Special emphasis is placed on building and sustaining multidisciplinary teams that bring together specialties to deliver coordinated, patient-centered care. The program also provides a unique opportunity to hear the patient’s perspective on their disease journey, as well as insights from a physician sharing clinical strategies successfully implemented to manage these disease symptoms.
TARGET AUDIENCE
This educational activity is intended for rheumatologists, gastroenterologists, dermatologists, and related advanced practice providers who care for patients with obesity and IMIDs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the immune messengers common to both obesity and IMIDs and their resultant corresponding pathologies
- Incorporate obesity treatment guideline recommendations and their supporting data into the management of patients with both IMIDs and excess body weight
- Develop and maintain a collaborative multidisciplinary team to optimize care for the patient with IMIDs and obesity
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Jerry Bagel, MD, MS | Consulting: Takeda, Galderma Speakers Bureau: AbbVie, Incyte, Bristol Myers Squibb, Galderma, Eli Lilly Contracted Research: AbbVie, Janssen, Incyte, Eli Lilly, Bristol Myers Squibb |
| Robin Ciesielski, Patient | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation & Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- La Donna Lue Winston, MSN, APRN, AGACNP-BC, SCRN, RN, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: March 18, 2026
EXPIRATION DATE: March 18, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Regulatory Update: Orforglipron – a daily, oral GLP-1 receptor agonist – received FDA approval on April 1, 2026, after the release of this educational activity.
PROGRAM CHAIR & FACULTY
Stephanie L. Gold, MD
Assistant Professor of Medicine
Division of Gastroenterology
Department of Medicine
Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital
New York, New York
FEATURING
Elizabeth Spencer
Brooklyn, New York
PROGRAM OVERVIEW
This “Day in the Life” Docuseries program explores the shared immunologic mechanisms underlying obesity and immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease, psoriasis, and psoriatic arthritis. It highlights the key cytokines and signaling pathways that drive chronic inflammation and contribute to comorbid pathology. Attendees will review current obesity guidelines and supporting evidence to inform integrated care strategies for patients with IMIDs and excess body weight. Special emphasis is placed on building and sustaining multidisciplinary teams that bring together specialties to deliver coordinated, patient-centered care. The program also provides a unique opportunity to hear the patient’s perspective on their disease journey, as well as insights from a physician sharing clinical strategies successfully implemented to manage these disease symptoms.
TARGET AUDIENCE
This educational activity is intended for rheumatologists, gastroenterologists, dermatologists, and related advanced practice providers who care for patients with obesity and IMIDs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the immune messengers common to both obesity and IMIDs and their resultant corresponding pathologies
- Incorporate obesity treatment guideline recommendations and their supporting data into the management of patients with both IMIDs and excess body weight
- Develop and maintain a collaborative multidisciplinary team to optimize care for the patient with IMIDs and obesity
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Stephanie L. Gold, MD | Has nothing to disclose. |
| Elizabeth Spencer, Patient | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation & Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- La Donna Lue Winston, MSN, APRN, AGACNP-BC, SCRN, RN, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: March 18, 2026
EXPIRATION DATE: March 18, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Regulatory Update: Orforglipron – a daily, oral GLP-1 receptor agonist – received FDA approval on April 1, 2026, after the release of this educational activity.
PROGRAM CHAIR & FACULTY
Adam Mayer, MD, MSCE
Adult and Pediatric Rheumatologist
Hackensack University Medical Center
Assistant Professor of Medicine and Pediatrics
Hackensack Meridian School of Medicine
Assistant Member, Center for Discovery and Innovation
Nutley, New Jersey
FEATURING
Jack Fleming
West Milford, New Jersey
PROGRAM OVERVIEW
This “Day in the Life” Docuseries program explores the shared immunologic mechanisms underlying obesity and immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease, psoriasis, and psoriatic arthritis. It highlights the key cytokines and signaling pathways that drive chronic inflammation and contribute to comorbid pathology. Attendees will review current obesity guidelines and supporting evidence to inform integrated care strategies for patients with IMIDs and excess body weight. Special emphasis is placed on building and sustaining multidisciplinary teams that bring together specialties to deliver coordinated, patient-centered care. The program also provides a unique opportunity to hear the patient’s perspective on their disease journey, as well as insights from a physician sharing clinical strategies successfully implemented to manage these disease symptoms.
TARGET AUDIENCE
This educational activity is intended for rheumatologists, gastroenterologists, dermatologists, and related advanced practice providers who care for patients with obesity and IMIDs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the immune messengers common to both obesity and IMIDs and their resultant corresponding pathologies
- Incorporate obesity treatment guideline recommendations and their supporting data into the management of patients with both IMIDs and excess body weight
- Develop and maintain a collaborative multidisciplinary team to optimize care for the patient with IMIDs and obesity
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Adam Mayer, MD, MSCE | Contracted research: Unpaid research with AbbVie Stock ownership: AbbVie, Eli Lilly |
| Jack Fleming, Patient | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation & Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- La Donna Lue Winston, MSN, APRN, AGACNP-BC, SCRN, RN, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: March 18, 2026
EXPIRATION DATE: March 18, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
